Merck KGaA Acquires Bio-Techne (TECH) for $11.3 Billion in Major Life Sciences Deal

Key Highlights

• German pharmaceutical company Merck KGaA to purchase Bio-Techne in $11.3 billion transaction
• Acquisition price set at $73 per share, representing a 24% premium over Wednesday’s close
• Bio-Techne shares climbed 20% to reach $70.58 during Thursday’s premarket session
• Transaction anticipated to finalize between late 2026 and early 2027
• Combined entity expected to generate cost synergies of approximately 140 million euros within three years post-closure

Shares of Bio-Techne (TECH) experienced a significant 20% rally to $70.58 during Thursday’s premarket session following the announcement that Germany’s Merck KGaA has reached a definitive agreement to acquire the biotechnology company for $11.3 billion.

Bio-Techne Corporation, TECH

The German pharmaceutical giant is paying $73 for each Bio-Techne share, which reflects a 24% markup compared to Wednesday’s closing quotation. Shares of Merck KGaA also experienced positive momentum, gaining 3% following the announcement.

This transaction represents Merck KGaA’s most substantial acquisition since 2014, when the company purchased Sigma-Aldrich in a similarly significant deal.

The buyout also marks the inaugural major strategic move by CEO Kai Beckmann, who assumed the leadership role in May, succeeding Belén Garijo.

Bio-Techne specializes in manufacturing research reagents, proteins, antibodies, and analytical equipment utilized by scientific researchers and pharmaceutical developers. The company’s extensive portfolio features 6,000 different proteins and an impressive collection of 425,000 antibodies.

During a Thursday morning media briefing, Merck’s Life Science CEO Jean-Charles Wirth described the comprehensive catalog as a “big, big plus” for the customer base.

Bolstering Life Sciences Operations

The strategic acquisition aims to strengthen Merck’s footprint in cutting-edge biological research and the rapidly expanding cell and gene therapy sectors.

According to Merck’s statement, this transaction solidifies life sciences as the cornerstone of the company’s future growth trajectory.

Leerink analyst Puneet Souda noted that Merck seems to be securing a compelling asset with robust long-term growth prospects, notwithstanding current challenges affecting the research tools sector.

Multiple analysts have indicated they don’t anticipate significant regulatory obstacles to the deal’s completion.

Financial Structure and Efficiency Gains

Merck intends to finance the acquisition through a combination of existing cash reserves and borrowed capital. The company reported holding roughly 2.74 billion euros in cash according to its latest quarterly financial statements.

The pharmaceutical company projects achieving operational efficiencies totaling approximately 140 million euros, with full realization expected by year three following transaction completion.

The deal’s closure is projected to occur sometime between late 2026 and early 2027.

This strategic acquisition aligns with a comprehensive M&A approach initiated during Garijo’s tenure, which encompassed the purchases of Exelead, Mirus Bio, and SpringWorks Therapeutics, spanning mRNA production capabilities, cell and gene therapy technologies, and rare disease therapeutics.

The post Merck KGaA Acquires Bio-Techne (TECH) for $11.3 Billion in Major Life Sciences Deal appeared first on Blockonomi.